November 2012

Date: 
November, 2012
Deck: 
Max Wallace, CEO of Accelerate Brain Cancer Cure, provides perspective on the latest Avastin trial results by Genentech.

Dear Friends,

I want to share with you the latest news on Avastin® (bevacizumab), a treatment for patients with glioblastoma, the most common and aggressive form of brain cancer. 

This fall, ABC2 supporters had the unique opportunity to learn first-hand about the latest advances in brain tumor research at a series of ABC2 Science Salon events across the country. 

Deck: 
A blog post from Max Wallace, CEO of Accelerate Brain Cancer Cure.

Our Annual Scientific Gathering is central to identifying, developing and funding research projects for the new year.

Subscribe to RSS - November 2012
Share |

Join us in our fight for a cure!

Twitter